Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients

Giuseppe Minniti, Marie Lise Jaffrain-Rea, Roberto Baldelli, Elisabetta Ferretti, Barbara Caracciolo, Antonella Bultrini, Alberto Gulino, Guido Tamburrano

Research output: Contribution to journalArticlepeer-review


Purpose: The acute GH lowering effects of a single dose of either octreotide (OCT) or cabergoline (CAB), given alone and in combination, were studied in a series of 21 patients with acromegaly. Patients and Methods: Plasma GH was measured for 8 hours after a single subcutaneous injection of OCT (100 μg) and for 48 hours after a single oral dose of CAB (0.5 mg) in all patients. Fourteen patients, who did not suppress GH levels below 5 μg/L after either OCT or CAB given alone, also received a combination of both drugs (OCT 100 μg s.c. + CAB 0.5 mg p.o. 24 h before OCT). Results: GH levels were acutely suppressed by more than 50 % in 15/21 cases after OCT alone and in 5/ 21after CAB alone, respectively (P <0.01). In the 14 patients who received the combined test, the magnitude of GH suppression was significantly higher than after OCT alone 4, 6 and 8 hours after OCT administration (P <0.02). In patients with mixed GH/PRL-secreting tumors, the additive effect of OCT and CAB was observed at each time point. Conclusion: These results suggest that combined therapy with OCT and CAB may be more effective in suppressing GH secretion than either compound given alone, especially in patients with GH/PRL-secreting adenomas.

Original languageEnglish
Pages (from-to)601-607
Number of pages7
JournalClinica Terapeutica
Issue number12
Publication statusPublished - Dec 1997


  • Acromegaly
  • Dopaminergic drugs
  • Growth hormone
  • Somatostatin analogs

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients'. Together they form a unique fingerprint.

Cite this